| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2652 | 2016 |
| Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome RW Tothill, AV Tinker, J George, R Brown, SB Fox, S Lade, DS Johnson, ... Clinical cancer research 14 (16), 5198-5208, 2008 | 1606 | 2008 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1234 | 2017 |
| Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study W Sieh, M Köbel, TA Longacre, DD Bowtell, A DeFazio, MT Goodman, ... The lancet oncology 14 (9), 853-862, 2013 | 488 | 2013 |
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 460 | 2017 |
| “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? A Davis, AV Tinker, M Friedlander Gynecologic oncology 133 (3), 624-631, 2014 | 446 | 2014 |
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 404 | 2017 |
| BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ... Cancer discovery 9 (2), 210-219, 2019 | 378 | 2019 |
| Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss B Clarke, AV Tinker, CH Lee, S Subramanian, M Van De Rijn, D Turbin, ... Modern Pathology 22 (3), 393-402, 2009 | 345 | 2009 |
| Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas D Etemadmoghadam, A Defazio, R Beroukhim, C Mermel, J George, ... Clinical cancer research 15 (4), 1417-1427, 2009 | 338 | 2009 |
| Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer … A Oaknin, AV Tinker, L Gilbert, V Samouëlian, C Mathews, J Brown, ... JAMA oncology 6 (11), 1766-1772, 2020 | 335 | 2020 |
| Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label … E Pujade-Lauraine, K Fujiwara, JA Ledermann, AM Oza, R Kristeleit, ... The Lancet Oncology 22 (7), 1034-1046, 2021 | 292 | 2021 |
| Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma S Böhm, A Faruqi, I Said, M Lockley, E Brockbank, A Jeyarajah, ... Journal of Clinical Oncology 33 (22), 2457-2463, 2015 | 284 | 2015 |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated … AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ... Gynecologic oncology 147 (2), 267-275, 2017 | 271 | 2017 |
| Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient … A Oaknin, L Gilbert, AV Tinker, J Brown, C Mathews, J Press, R Sabatier, ... Journal for immunotherapy of cancer 10 (1), 2022 | 261 | 2022 |
| Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas MS Anglesio, S Kommoss, MC Tolcher, B Clarke, L Galletta, H Porter, ... The Journal of pathology 229 (1), 111-120, 2013 | 259 | 2013 |
| Clinical trials in recurrent ovarian cancer M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ... International Journal of Gynecologic Cancer 21 (4), 2011 | 247 | 2011 |
| Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers JS Kwon, A Tinker, G Pansegrau, J McAlpine, M Housty, M McCullum, ... Obstetrics & Gynecology 121 (1), 14-24, 2013 | 227 | 2013 |
| The role of the fallopian tube in ovarian cancer AA Tone, S Salvador, SJ Finlayson, AV Tinker, JS Kwon, CH Lee, ... Clin Adv Hematol Oncol 10 (5), 296-306, 2012 | 164 | 2012 |
| Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) EM Swisher, TT Kwan, AM Oza, AV Tinker, I Ray-Coquard, A Oaknin, ... Nature communications 12 (1), 2487, 2021 | 161 | 2021 |
